Cytology identified CD markers (CD10, CD19, CD20) consistent with stage IV follicular lymphoma. The patient was treated with six cycles of R-CHOP (rituximab, vincristine, cyclophosphamide, and prednisone) chemotherapy and required a pleurX catheter for recurrent effusions, achieving partial symptomatic control. This evidence concerns the gene CD19 and follicular lymphoma.